{
    "thread": {
        "uuid": "ee5b50e14fc4d0eef9061aa51fb212fed2ce1bca",
        "url": "https://www.americanbankingnews.com/2025/01/10/brookline-capital-management-forecasts-crsp-fy2024-earnings.html",
        "site_full": "www.americanbankingnews.com",
        "site": "americanbankingnews.com",
        "site_section": "https://www.americanbankingnews.com",
        "site_categories": [
            "financial_news",
            "finance"
        ],
        "section_title": "American Banking and Market News",
        "title": "Brookline Capital Management Forecasts CRSP FY2024 Earnings",
        "title_full": "Brookline Capital Management Forecasts CRSP FY2024 Earnings",
        "published": "2025-01-10T07:12:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 138244,
        "domain_rank_updated": "2025-01-06T23:00:00.000+02:00",
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "ee5b50e14fc4d0eef9061aa51fb212fed2ce1bca",
    "url": "https://www.americanbankingnews.com/2025/01/10/brookline-capital-management-forecasts-crsp-fy2024-earnings.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "ABMN Staff",
    "published": "2025-01-10T07:12:00.000+02:00",
    "title": "Brookline Capital Management Forecasts CRSP FY2024 Earnings",
    "text": "CRISPR Therapeutics AG ( NASDAQ:CRSP – Free Report ) – Brookline Capital Management increased their FY2024 earnings estimates for shares of CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($5.16) per share for the year, up from their prior forecast of ($5.18). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share. Several other research analysts also recently issued reports on CRSP. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $78.38. Get Our Latest Stock Report on CRSP NASDAQ CRSP opened at $41.29 on Thursday. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68. CRISPR Therapeutics has a twelve month low of $38.20 and a twelve month high of $91.10. The business’s fifty day moving average is $46.50 and its 200 day moving average is $48.88. CRISPR Therapeutics ( NASDAQ:CRSP – Get Free Report ) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm posted ($1.41) earnings per share. A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $35,000. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics in the 3rd quarter worth about $43,000. National Bank of Canada FI increased its stake in CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares during the last quarter. Finally, Elkhorn Partners Limited Partnership bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $54,000. 69.20% of the stock is owned by hedge funds and other institutional investors. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 1.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold a total of 50,382 shares of company stock valued at $2,744,179 over the last ninety days. 4.10% of the stock is owned by corporate insiders. ( Get Free Report )CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Economy, Business and Finance"
    ],
    "topics": [
        "Economy, Business and Finance->financial and economic news",
        "Economy, Business and Finance->business reporting and performance"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [
        "http://www.sec.gov/Archives/edgar/data/1674416/000095017024114786/xslF345X05/ownership.xml",
        "http://www.sec.gov/Archives/edgar/data/1674416/000095017024114787/xslF345X05/ownership.xml",
        "https://report.stocknews.com/sign-up/ticker/?ticker=CRSP&lead_source=marketbeat_snra&utm_source=marketbeat_snra&utm_medium=article&utm_campaign=ticker&utm_term=CRSP&utm_content=text_link",
        "https://www.insidertrades.com/crispr-therapeutics-ag-stock/samarth-kulkarni/",
        "https://www.marketbeat.com/stocks/NASDAQ/CRSP/earnings/",
        "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=CRSP",
        "https://www.marketbeat.com/stocks/NASDAQ/CRSP/",
        "https://www.insidertrades.com/crispr-therapeutics-ag-stock/samarth-kulkarni",
        "http://sec.gov/Archives/edgar/data/1674416/000095017024114787/xslF345X05/ownership.xml",
        "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx",
        "https://marketbeat.com/stocks/NASDAQ/CRSP/",
        "https://marketbeat.com/stocks/NASDAQ/CRSP/earnings/",
        "https://www.report.stocknews.com/sign-up/ticker/?ticker=CRSP&lead_source=marketbeat_snra&utm_source=marketbeat_snra&utm_medium=article&utm_campaign=ticker&utm_term=CRSP&utm_content=text_link",
        "https://marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=CRSP",
        "https://www.marketbeat.com/stocks/NASDAQ/CRSP",
        "https://www.marketbeat.com/stocks/NASDAQ/CRSP/earnings",
        "https://insidertrades.com/crispr-therapeutics-ag-stock/samarth-kulkarni/",
        "http://sec.gov/Archives/edgar/data/1674416/000095017024114786/xslF345X05/ownership.xml",
        "https://report.stocknews.com/sign-up/ticker/"
    ],
    "external_images": [],
    "entities": {
        "persons": [],
        "organizations": [],
        "locations": []
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "rating": null,
    "crawled": "2025-01-10T08:55:26.176+02:00",
    "updated": "2025-01-10T08:55:26.176+02:00"
}